Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antagonist activity at c-IAP1 (unknown origin)
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Antagonist activity at N-terminal His-tagged cIAP2-BIR3 domain (unknown origin) expressed in Escherichia coli BL21 using AVPIAQKSEK-biotinylated peptide as substrate preincubated for 2 hrs with protein followed by substrate addition measured after 2 hrs by DELFIA assay
Assay data:3 Active, 3 Activity ≤ 1 µM, 3 Tested
Antagonist activity at N-terminal His-tagged cIAP1-BIR3 domain (unknown origin) expressed in Escherichia coli BL21 using AVPIAQKSEK-biotinylated peptide as substrate preincubated for 2 hrs with protein followed by substrate addition measured after 2 hrs by DELFIA assay
Antagonist activity at N-terminal His-tagged cIAP2-BIR3 domain (unknown origin) expressed in Escherichia coli BL21 using AVPIAQKSEK-biotinylated peptide as substrate incubated for 2 hrs by DELFIA assay
Assay data:10 Active, 10 Activity ≤ 1 µM, 12 Tested
Antagonist activity at N-terminal His-tagged cIAP1-BIR3 domain (unknown origin) expressed in Escherichia coli BL21 using AVPIAQKSEK-biotinylated peptide as substrate incubated for 2 hrs by DELFIA assay
Assay data:11 Active, 12 Activity ≤ 1 µM, 12 Tested
Biological Assay 1: affinity of compounds to cIAP1-BIR3, cIAP2-BIR3, XIAP-BIR3 from US Patent US10508103: "Benzimidazole-linked indole compound acting as novel divalent IAP antagonist"
Assay data:29 Active, 29 Activity ≤ 1 µM, 29 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
TR-FRET Assays for cIAP BIR3 from US Patent US10398702: "Dimeric compounds"
Assay data:27 Active, 27 Activity ≤ 1 µM, 27 Tested
TR-FRET Assays for cIAP BIR2 from US Patent US10398702: "Dimeric compounds"
Assay data:21 Active, 16 Activity ≤ 1 µM, 27 Tested
Enzyme Inhibition from US Patent US10392346: "Kinase inhibitors"
Assay data:39 Active, 39 Activity ≤ 1 µM, 39 Tested
Binding Assays (DELFIA) from US Patent US9481673: "6-alkynyl-pyridine derivatives"
Assay data:16 Active, 12 Activity ≤ 1 nM, 16 Activity ≤ 1 µM, 16 Tested
XIAP BIR3 & cIAP1 BIR3 Binding Assays (DELFIA) from US Patent US9278978: "6-Alkynyl Pyridine"
Assay data:42 Active, 22 Activity ≤ 1 nM, 40 Activity ≤ 1 µM, 42 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
DELFIA Assay from US Patent US9249151: "Bis-amido pyridines"
Assay data:60 Active, 19 Activity ≤ 1 nM, 54 Activity ≤ 1 µM, 60 Tested
In Vitro Competitive Displacement Binding Assay from US Patent US9155743: "Bicyclic heterocycle compounds and their uses in therapy"
Assay data:39 Active, 37 Activity ≤ 1 µM, 44 Tested
In vitro Competitive Displacement Binding Assays from US Patent US9018214: "Bicyclic heterocycle compounds and their uses in therapy"
Assay data:202 Active, 175 Activity ≤ 1 µM, 217 Tested
Fluorescence Polarization (FP) Based Competitive Assay from US Patent US8883771: "Bivalent inhibitors of IAP proteins and therapeutic methods using the same"
Assay data:50 Active, 41 Activity ≤ 1 µM, 50 Tested
Fluorescence Polarization-Based Assays from US Patent US8815927: "Bivalent diazo bicyclic Smac mimetics and the uses thereof"
Assay data:6 Active, 6 Activity ≤ 1 µM, 6 Tested
Fluorescence Polarization Assay from Article 10.1016/j.bmc.2009.07.009: "Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy."
Assay data:36 Active, 36 Activity ≤ 1 µM, 36 Tested
Fluorescence Polarization Affinity Measurements from Article 10.1021/cb900083m: "Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists."
Assay data:4 Active, 4 Activity ≤ 1 µM, 5 Tested
Fluorescence Polarization Affinity Measurements from Article 10.1021/jm801450c: "Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold."
Assay data:25 Active, 17 Activity ≤ 1 µM, 25 Tested
Fluorescence Polarization Assay from Article 10.1021/jm801146d: "Design, Synthesis, and Evaluation of Tricyclic, Conformationally Constrained Small-Molecule Mimetics of Second Mitochondria-Derived Activator of Caspases."
Assay data:5 Active, 5 Activity ≤ 1 µM, 5 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on